Recommendation of the President – Adderall XR (amphetamine/dextroamphetamine)

On 19 September 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation on the appropriateness of authorizing the reimbursement of Adderall XR (amphetamine/dextroamphetamine) for the indication: treatment of attention deficit hyperactivity disorder (ADHD) (ICD-10: F90.1)

Publication in Public Information Bulletin (BIP) >>